GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Dividend-Payout-to-FFO

TME Pharma NV (FRA:0N6A) Dividend-Payout-to-FFO


View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


TME Pharma NV Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).